Wedbush Maintains Outperform on Longboard Pharmaceuticals, Raises Price Target to $34
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst Laura Chico maintains an Outperform rating on Longboard Pharmaceuticals (NASDAQ:LBPH) and raises the price target from $32 to $34.
May 03, 2024 | 1:40 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Wedbush analyst Laura Chico maintains an Outperform rating on Longboard Pharmaceuticals and raises the price target from $32 to $34.
The increase in price target by a reputable analyst suggests a positive outlook on the company's future performance, likely leading to increased investor confidence and potentially a rise in stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100